Envisagenics

Envisagenics

Envisagenics is an AI-driven biotechnology company founded in 2014 as a spin-out from the Cold Spring Harbor Laboratory that harnesses the therapeutic potential of RNA splicing.

Alternative splicing holds the key to understanding and targeting over 370 diseases, including cancer and neurodegenerative disorders.

Leveraging an extensive map of over 14 million RNA splicing events, Envisagenics’ SpliceCore platform enables the discovery of disease-specific targets, paving the way for the rational design and development of RNA therapeutics and immunotherapies.

Envisagenics currently has several programs focused on various cancer and disease indications, including Multiple Myeloma and other hematologic malignancies and has entered into multiple Pharma research collaborations.